{"entity":{"type":"insider","cik":"0001561458","url":"/insider/0001561458","json_url":"/insider/0001561458.json","name":"Fridriksdottir Hafrun","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":29,"n_filings":22,"first":"2018-03-20","last":"2022-05-19","span_basis":"filed_date"},"name_variants":[{"name":"Fridriksdottir Hafrun","source":"filing","n_filings":22,"first_seen":"2018-03-20","last_seen":"2022-05-19"}],"transactions":[{"id":6125401,"accession":"0001209191-22-030308","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-030308","line_url":"/filing/0001209191-22-030308#line-1","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":130000.0,"shares_display":"130,000","price_per_share":8.2159,"price_display":"8.22","price_state":"stated","total_value":1068067.0,"total_display":"1,068,067.00","total_whole":"1,068,067","shares_owned_after":1386.514,"shares_owned_after_display":"1,386.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-17","filed_date":"2022-05-19","scope":"insider"},{"id":6919926,"accession":"0001209191-22-017046","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-22-017046","line_url":"/filing/0001209191-22-017046#line-6","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8941.0,"shares_display":"8,941","price_per_share":7.3667,"price_display":"7.37","price_state":"stated","total_value":65865.6647,"total_display":"65,865.66","total_whole":"65,866","shares_owned_after":126086.514,"shares_owned_after_display":"126,086.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-07","filed_date":"2022-03-08","scope":"insider"},{"id":6919918,"accession":"0001209191-22-017046","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-22-017046","line_url":"/filing/0001209191-22-017046","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24638.0,"shares_display":"24,638","price_per_share":7.4825,"price_display":"7.48","price_state":"stated","total_value":184353.835,"total_display":"184,353.84","total_whole":"184,354","shares_owned_after":98976.514,"shares_owned_after_display":"98,976.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-04","filed_date":"2022-03-08","scope":"insider","n_lines":2},{"id":6097156,"accession":"0001209191-22-014469","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-014469","line_url":"/filing/0001209191-22-014469#line-2","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7590.0,"shares_display":"7,590","price_per_share":8.1422,"price_display":"8.14","price_state":"stated","total_value":61799.298,"total_display":"61,799.30","total_whole":"61,799","shares_owned_after":65508.514,"shares_owned_after_display":"65,508.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-28","filed_date":"2022-03-02","scope":"insider"},{"id":6541839,"accession":"0001209191-22-008415","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-008415","line_url":"/filing/0001209191-22-008415#line-2","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6116.0,"shares_display":"6,116","price_per_share":9.0602,"price_display":"9.06","price_state":"stated","total_value":55412.1832,"total_display":"55,412.18","total_whole":"55,412","shares_owned_after":51416.514,"shares_owned_after_display":"51,416.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-09","filed_date":"2022-02-10","scope":"insider"},{"id":4485467,"accession":"0001209191-21-051075","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-051075","line_url":"/filing/0001209191-21-051075#line-1","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50860.0,"shares_display":"50,860","price_per_share":9.9493,"price_display":"9.95","price_state":"stated","total_value":506021.398,"total_display":"506,021.40","total_whole":"506,021","shares_owned_after":41411.514,"shares_owned_after_display":"41,411.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-10","filed_date":"2021-08-12","scope":"insider"},{"id":5100177,"accession":"0001209191-21-032252","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-032252","line_url":"/filing/0001209191-21-032252#line-2","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19066.0,"shares_display":"19,066","price_per_share":10.2187,"price_display":"10.22","price_state":"stated","total_value":194829.7342,"total_display":"194,829.73","total_whole":"194,830","shares_owned_after":92271.514,"shares_owned_after_display":"92,271.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-11","filed_date":"2021-05-13","scope":"insider"},{"id":4224336,"accession":"0001209191-21-018518","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-018518","line_url":"/filing/0001209191-21-018518#line-2","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9515.0,"shares_display":"9,515","price_per_share":10.5661,"price_display":"10.57","price_state":"stated","total_value":100536.4415,"total_display":"100,536.44","total_whole":"100,536","shares_owned_after":73453.514,"shares_owned_after_display":"73,453.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-04","filed_date":"2021-03-08","scope":"insider"},{"id":5374716,"accession":"0001209191-21-017758","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-017758","line_url":"/filing/0001209191-21-017758#line-1","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":10.8178,"price_display":"10.82","price_state":"stated","total_value":540890.0,"total_display":"540,890.00","total_whole":"540,890","shares_owned_after":64063.514,"shares_owned_after_display":"64,063.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-02","filed_date":"2021-03-04","scope":"insider"},{"id":4925538,"accession":"0001209191-21-015842","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-015842","line_url":"/filing/0001209191-21-015842#line-2","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10912.0,"shares_display":"10,912","price_per_share":10.8308,"price_display":"10.83","price_state":"stated","total_value":118185.6896,"total_display":"118,185.69","total_whole":"118,186","shares_owned_after":114063.514,"shares_owned_after_display":"114,063.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-01","filed_date":"2021-03-02","scope":"insider"},{"id":5520084,"accession":"0001209191-21-011244","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-011244","line_url":"/filing/0001209191-21-011244#line-2","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2098.0,"shares_display":"2,098","price_per_share":11.1229,"price_display":"11.12","price_state":"stated","total_value":23335.8442,"total_display":"23,335.84","total_whole":"23,336","shares_owned_after":103293.514,"shares_owned_after_display":"103,293.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-16","filed_date":"2021-02-17","scope":"insider"},{"id":5422700,"accession":"0001209191-21-009633","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-009633","line_url":"/filing/0001209191-21-009633","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29496.0,"shares_display":"29,496","price_per_share":12.6945,"price_display":"12.69","price_state":"stated","total_value":374436.972,"total_display":"374,436.97","total_whole":"374,437","shares_owned_after":100036.514,"shares_owned_after_display":"100,036.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-09","filed_date":"2021-02-11","scope":"insider","n_lines":2},{"id":2075532,"accession":"0001209191-20-020163","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-020163","line_url":"/filing/0001209191-20-020163","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":514.0,"shares_display":"514","price_per_share":7.1635,"price_display":"7.16","price_state":"stated","total_value":3682.039,"total_display":"3,682.04","total_whole":"3,682","shares_owned_after":45694.514,"shares_owned_after_display":"45,694.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-03-17","filed_date":"2020-03-19","scope":"insider","n_lines":2},{"id":2487393,"accession":"0001209191-20-009879","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-009879","line_url":"/filing/0001209191-20-009879","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11472.0,"shares_display":"11,472","price_per_share":12.1422,"price_display":"12.14","price_state":"stated","total_value":139295.3184,"total_display":"139,295.32","total_whole":"139,295","shares_owned_after":45060.514,"shares_owned_after_display":"45,060.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-14","filed_date":"2020-02-18","scope":"insider","n_lines":2},{"id":2224445,"accession":"0001209191-20-008164","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-008164","line_url":"/filing/0001209191-20-008164#line-2","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5544.0,"shares_display":"5,544","price_per_share":12.27,"price_display":"12.27","price_state":"stated","total_value":68024.88,"total_display":"68,024.88","total_whole":"68,025","shares_owned_after":33329.514,"shares_owned_after_display":"33,329.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-10","filed_date":"2020-02-11","scope":"insider"},{"id":2115222,"accession":"0001209191-20-000005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-000005","line_url":"/filing/0001209191-20-000005#line-2","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2459.0,"shares_display":"2,459","price_per_share":9.9212,"price_display":"9.92","price_state":"stated","total_value":24396.2308,"total_display":"24,396.23","total_whole":"24,396","shares_owned_after":22753.514,"shares_owned_after_display":"22,753.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-31","filed_date":"2020-01-02","scope":"insider"},{"id":8069627,"accession":"0001209191-19-058620","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-058620","line_url":"/filing/0001209191-19-058620#line-2","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4310.0,"shares_display":"4,310","price_per_share":10.4906,"price_display":"10.49","price_state":"stated","total_value":45214.486,"total_display":"45,214.49","total_whole":"45,214","shares_owned_after":20572.514,"shares_owned_after_display":"20,572.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-02","filed_date":"2019-12-03","scope":"insider"},{"id":7867989,"accession":"0001209191-19-020157","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-19-020157","line_url":"/filing/0001209191-19-020157","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":356.0,"shares_display":"356","price_per_share":16.6251,"price_display":"16.63","price_state":"stated","total_value":5918.5356,"total_display":"5,918.54","total_whole":"5,919","shares_owned_after":16842.514,"shares_owned_after_display":"16,842.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-18","filed_date":"2019-03-19","scope":"insider","n_lines":2},{"id":7800861,"accession":"0001209191-19-016085","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-016085","line_url":"/filing/0001209191-19-016085#line-2","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":409.0,"shares_display":"409","price_per_share":16.8833,"price_display":"16.88","price_state":"stated","total_value":6905.2697,"total_display":"6,905.27","total_whole":"6,905","shares_owned_after":16093.514,"shares_owned_after_display":"16,093.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-04","filed_date":"2019-03-05","scope":"insider"},{"id":7836365,"accession":"0001209191-19-010837","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-010837","line_url":"/filing/0001209191-19-010837#line-2","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1841.0,"shares_display":"1,841","price_per_share":17.669,"price_display":"17.67","price_state":"stated","total_value":32528.629,"total_display":"32,528.63","total_whole":"32,529","shares_owned_after":15337.514,"shares_owned_after_display":"15,337.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-14","filed_date":"2019-02-19","scope":"insider"},{"id":8614810,"accession":"0001209191-19-000609","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-000609","line_url":"/filing/0001209191-19-000609#line-2","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1643.0,"shares_display":"1,643","price_per_share":15.7025,"price_display":"15.70","price_state":"stated","total_value":25799.2075,"total_display":"25,799.21","total_whole":"25,799","shares_owned_after":11825.514,"shares_owned_after_display":"11,825.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-02","filed_date":"2019-01-03","scope":"insider"},{"id":6143120,"accession":"0001209191-18-060707","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-060707","line_url":"/filing/0001209191-18-060707#line-2","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":933.0,"shares_display":"933","price_per_share":21.7621,"price_display":"21.76","price_state":"stated","total_value":20304.0393,"total_display":"20,304.04","total_whole":"20,304","shares_owned_after":8828.514,"shares_owned_after_display":"8,828.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-11-30","filed_date":"2018-12-04","scope":"insider"},{"id":5960676,"accession":"0001209191-18-020859","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-020859","line_url":"/filing/0001209191-18-020859","is_derivative":false,"issuer_cik":"0000818686","issuer_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","issuer_ticker":"TEVA","issuer_name_source":null,"issuer_url":"/issuer/0000818686","owner_cik":"0001561458","owner_name":"Fridriksdottir Hafrun","owner_display_name":"Fridriksdottir Hafrun","owner_url":"/insider/0001561458","role":"Officer (Executive VP, Global R&D)","role_mark":"O","role_mark_label":"Officer (Executive VP, Global R&D)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Executive VP, Global R&D","security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":348.0,"shares_display":"348","price_per_share":17.878,"price_display":"17.88","price_state":"stated","total_value":6221.544,"total_display":"6,221.54","total_whole":"6,222","shares_owned_after":7141.514,"shares_owned_after_display":"7,141.51","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-19","filed_date":"2018-03-20","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":29,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":29,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":29},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000818686","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","url":"/issuer/0000818686","role":"Officer (Executive VP, Global R&D)","n_filings":22,"first_seen":"2018-03-20","last_seen":"2022-05-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001561458","retrieved_at":"2026-08-27T06:14:04+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}